bioRxiv · 10.1101/2023.04.03.535285
Chemo-phosphoproteomic profiling with ATR inhibitors berzosertib and gartisertib uncovers new biomarkers and DNA damage response regulators
Abstract
The ATR kinase protects cells against DNA damage and replication stress and represents a promising anti-cancer drug target. The ATR inhibitors (ATRi) berzosertib and gartisertib are in clinical trials for treatment of advanced solid tumours as monotherapy or in combination with genotoxic agents. However, the pharmacodynamic ATR biomarker phospho-CHK1 has shown limited sensitivity in for quantitative assessment of ATR activity in clinical trials. Therefore, better biomarkers are needed, and with this in mind we carried out quantitative phospho-proteomic screening for ATR biomarkers that are highly sensitive to berzosertib and gartisertib. Screening identified novel ATR-dependent targets in three broad classes: i) targets whose phosphorylation is highly sensitive to ATRi; ii) novel targets with known genome maintenance roles; iii) novel targets whose cellular roles are unclear, including SCAF1. We show that SCAF1 interacts with RNAPII in a phospho-dependent manner and suppresses homologous recombination in cells lacking the BRCA1 tumour suppressor. Taken together these data reveal potential new ATR biomarkers and new genome maintenance factors.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Jadav, R. S., Weiland, F., Noordermeer, S. M., Carroll, T., Gao, Y., Wang, J., Zhou, H., Lamoliatte, F., Munoz, I., Toth, R., Macartney, T., Brown, F., Hastie, C. J., Alabert, C., van Attikum, H., Zenke, F., Masson, J.-Y., Rouse, J.. 2023-04-03. Chemo-phosphoproteomic profiling with ATR inhibitors berzosertib and gartisertib uncovers new biomarkers and DNA damage response regulators. https://doi.org/10.1101/2023.04.03.535285
Cite the original work for its findings. Save a collection to share your selection of sources.